AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) CEO Tom Equels talks to Proactive about how its drug Ampligen has been featured in the peer-reviewed medical journal Cancers as a potential treatment option for cancer patients infected with SARS-CoV-2.
The study’s authors stated that Ampligen has the potential to reduce the severity of the deadly respiratory disease COVID-19. Equels also gave an update on its Phase 1 clinical study to assess the safety, tolerability, and biological activity of its flagship drug Ampligen as a potential intranasal therapy.